Sodium alginate as a novel therapeutic option in experimental colitis

Scand J Immunol. 2005 Apr;61(4):316-21. doi: 10.1111/j.1365-3083.2005.01571.x.

Abstract

The potential therapeutic effect of low-viscosity sodium alginate (LVA) was studied in a rat model of acute colitis induced by intracolonic administration of acetic acid. This experimental model produced a significant ulcerative colitis. Induction of colitis also significantly enhanced the serum and colonic mucosal cytokine (IL-6 and TNF-alpha) and eicosanoid (LTB4 and PGE2) levels, which paralleled with the severity of colitis. LVA solution was administered orally as drinking water at concentration of 0.5% (W/V) for 1 week. The tolerability and inhibitory effect of LVA on matrix metalloproteinase-2 (MMP-2) were tested using WEHI-164 cell line and zymography method. The results showed that LVA therapy is able to significantly reduce colonic damage score, histological lesion, serum and colonic mucosal IL-6, TNF-alpha, LTB4 and PGE2 levels in treated group compared with nontreated controls. Moreover, in vitro examinations revealed that treatment with LVA could diminish MMP-2 activity. It is concluded that LVA is able to suppress acetic acid-induced colitis in rats. Some of the action of LVA may be associated with its inhibitory effects on cytokine and eicosanoid production and MMP-2 activity. Our data suggest that LVA could potentially be a novel therapeutic option for inflammatory bowel disease.

MeSH terms

  • Alginates / pharmacology*
  • Animals
  • Cell Line, Tumor
  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / immunology
  • Colitis, Ulcerative / pathology
  • Dinoprostone / blood
  • Disease Models, Animal
  • Electrophoresis, Polyacrylamide Gel
  • Female
  • Glucuronic Acid / pharmacology*
  • Hexuronic Acids / pharmacology*
  • Histocytochemistry
  • Humans
  • Interleukin-6 / blood
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / immunology
  • Intestinal Mucosa / pathology
  • Leukotriene B4 / blood
  • Matrix Metalloproteinase 2 / immunology
  • Matrix Metalloproteinase Inhibitors
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Alginates
  • Hexuronic Acids
  • Interleukin-6
  • Matrix Metalloproteinase Inhibitors
  • Tumor Necrosis Factor-alpha
  • Leukotriene B4
  • Glucuronic Acid
  • Matrix Metalloproteinase 2
  • Dinoprostone